Serum levels of PAI-1 and t-PA and the PAI-1/t-PA ratio were signifi cantly increased in diabetic patients with higher UAE. Impaired fi brinolysis and increased UAE were associated with renal disease progression.
Introduction
It is well known that vascular injury and cardiovascular diseases are the main causes of death in diabetic patients [1] and diabetes is one of the most important cause s of end-stage renal disease [2] .
Fibrosis is the hallmark for the development of end-stage kidney disease. Th is process occurs as a result of abnormal deposition of extracellular mat rix (ECM) in the basement membranes and interstitial tissues, associated with necrosis of the normal parenchymal cells and or apoptosis [3] . Replacement and degradation of the normal ECM by abnormal ECM is due to an increase in the proteolytic activity that is represented in the plasminogen activation system and matrix metalloproteinases [4] .
Plasminogen activator inhibitor-1 (PAI-1) is a single-chain glycoprotein [5] , the main inhibitor of the plasminogen activation system. It regulates intravascular fi brin deposition through the inhibition of the serine prote ases tissue-type plasminogen activator (t-PA) and urokinase type PA and plasmin-mediated matrix metalloproteinase activation [6] . Also, PAI-1 is a component of ECM that binds to vitronectin (also know n as protein S) [3] . Th is binding stabilizes PAI-1 in its active form and leads to the continuous inhibition of plasmin formation and matrix metalloproteinase Urinary albumin excretion and progression of renal disease with impaired fi brinolytic activity in type 2 diabetes mellitus Ebtessam Zakaria a , Maha Hossam Al-Din a , Nashwa S. Ghanem a , Noha A. Sadik a , Maha Assem a , Fatma Taha b
Background Diabetic nephropathy is one of the major causes of end-stage renal disease. As impaired fi brinolysis can increase renal fi brosis, we investigated the relationship of impaired fi brinolysis, as assessed by the ratio of plasminogen activator inhibitor-1 ( PAI-1) to tissue-type plasminogen activator (t-PA) with urinary albumin excretion ( UAE) and renal disease progression in type 2 diabetes.
Patients and methods
A total of 50 patients with type 2 diabetes and 10 healthy control individuals were included in the study. Participants were subdivided according to UAE. Group 1 (G1) represented control individuals. Group 2 (G2) included patients without albuminuria. Group 3 (G3) included patients with microalbuminuria. Group 4 (G4) included patients with macroalbuminuria. Creatinine clearance and UAE were calculated. PAI-1 and t-PA were measured using an enzyme-linked immunosorbent assay kit, and the PAI-1/t-PA ratio was calculated as an index of impaired fi brinolysis.
Results
PAI-1 was highly elevated signifi cantly in G4 when compared with the other groups, with a mean of 87.40 ± 17.03 IU/ml against 28.00 ± 6.98 IU/ml in G1, 46.4 ± 7.99 IU/ml in G2, and 64.10 ± 18.26 IU/ml in G3 (P < 0.001). Also, the serum level of t-PA in G4 was highly elevated signifi cantly when compared with G1 and G2 with means of 16.85 ± 5.63 IU/ml against 7.95 ± 1.91 IU/ml and 10.45 ± 2.63 IU/ml, respectively (P < 0.001). The ratio of PAI-1/t-PA in G4 was signifi cantly higher when compared with G1 (mean of 5.94 ± 2.81 against 3.54 ± 0.43; P = 0.01). PAI-1 and t-PA showed a signifi cant positive correlation with UAE. Receiver operating characteristics curve analysis revealed that only PAI-1 and t-PA were signifi cant discriminated factors for microalbuminuria and macroalbuminuria (P < 0.001). activation [7] . In addition, PAI-1 has the ability to promote fi brosis through its eff ect on infl ammatory cell recruitment, matrix turnover, fi broblast activation, and deposition [8] .
In the nondiseased kidney, PAI-1 is almost absent; increased expression was found in many chronic kidney diseases leading to renal fi brosis and endstage kidney failure [3] . Tumor growth factor-β and the renin-angiotensin-aldosterone system are the main inducers of PAI-1 expression, and their inhibition decreases PAI-1 expression in the glomerulus [9, 10] .
Th e resultant fi brosis and vascular injury that occurs in the kidney may be one of the most important factors that lead to glomerular capillary leakage of proteins and resultant albuminuria [11] . Th e increase in urinary albumin excretion (UAE) refl ects the vascular damage all over the body [12] , which may lead to the progression of diabetic nephropathy in type 2 diabetic patients [13] .
Th e aim from our study was to detect the relation of impaired fi brinolysis, as assessed by the ratio of the PAI-1 to the t-PA to UAE and the progression of renal disease in type 2 diabetes.
Patients and methods

Participants
A total of 50 patients with type 2 diabetes who attended the outpatient clinic of the Department of Internal Medicine, Kasr Al Aini Hospital, Cairo University, and 10 healthy age-matched control individuals were included in the study. All diabetic patients met the diagnostic criteria of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [14] . The study was performed from December 2013 to August 2014. Participants were subdivided into four groups with regard to UAE. Group 1 represented the control group. Group 2 included patients with type 2 diabetes without albuminuria. Group 3 included patients with type 2 diabetes with microalbuminuria. Group 4 included patients with type 2 diabetes with macroalbuminuria.
All patients had diabetes of type 2 of 8-10 years' duration.
Exclusion criteria
Patients with end-stage renal failure, congestive heart failure, cerebral infarction, cerebral hemorrhage, and liver diseases were excluded.
Ethical aspects
Research protocols were approved by the medical ethics committee of Kasr al Aini Medical School, Cairo University. All participants provided a written informed consent after the research protocols were explained carefully to them. Informed consent was obtained from all the study participants and their approval was taken by signature.
Procedures
All participants underwent a complete screening panel, including history taking and physical examination. Laboratory investigation included the following: fasting blood sugar, 2-h postprandial blood sugar, hemogl obin A 1C (HbA1c), total cholesterol, triglycerides, and serum creatinine. All laboratory investigations were performed by an autoanalyzer on Roche Diagnostic Mannheim GmbH (Germany). Creatinine clearance and UAE were calculated. PAI-1 and t-PA were measured using the enzyme-linked immunosorbent assay kit, and the PAI-1/t-PA ratio was calculated as an index of impaired fi brinolysis.
Creatinine clearance was calculated using the Cockroft-Gault equation in mg/dl [15] .
(140-age) [Wt (kg)]/72 (serum creatinine in mg/dl). If the patient is female, multiply the above by 0.85. UAE was calculated as 24-h urine collection. No albuminuria was considered if the albumin excretion in the urine was less than 30 mg/24 h. Microalbuminuria was considered if albumin excretion in the urine was in the range between 30 and 300 mg/24 h. Macroalbuminuria was considered if the albumin excretion was more than 300 mg/24 h.
PAI-1 (IU/ml) and t-PA (IU/ml) kits were supplied from H yphen BioMed (USA). Th e com plete enzymelinked immunosorbent assay kit was used for t issue-PAI-1 and for t-PA antigen.
Specimen collection
Blood was collect ed on EDTA through a clean venipuncture avoiding any blood activation; it was then decanted after a 20-min centrifugation at 2500 g to avoid platelet activation, stored frozen at -20°C or below for up to 6 months, and thawed for 15 min at 37°C just before use. To avoid diurnal variation, PAI-1 and t-PA were measured on fasting samples collected at morning. Th e Zymutest PAI-1 antigen kit is a one -step, tw o-site immunoassay for measuring human tissue-PAI-1 in the plasma. Th e measurement of PAI-1 was based on the method described by Declerck et al. [16] . Th e Zymutest t-PA ki t is a tw o-site immunoassay for measuring human t-PA in the plasma. Th e measurement of t-PA was based on the method described by Juhan-Vague et al. [17] .
Statistical analysis
Data was analyzed through statistical package of social science software program, version 18 (SPSS).Statistical Package for the Social Science; SPSS Inc., Chicago, Illinois, USA.
Data were summarized using mean and SD for quantitative variables and frequency and percentage for qualitative variables.
A comparison between groups was performed using the o ne-way analysis of variance test for quantitative variables with the post-hoc Tukey's test for pairwise compari sons and the χ 2 -test for qualitative variables. Th e Spearman correlation coeffi cient was calculated to test the association between quantitative variables. Receiver operating characteristics (ROC) analysis was used to test the discriminatory ability of certain measures to predict microalbuminuria and macroalbuminuria and to derive the most s uitable cutoff point with considerable sensitivity and specifi city. P values equal to or less than 0.05 were considered statistically signifi cant.
Results
Our patients have type 2 diabetes of 8-10 years' duration. Th e demographic and laboratory data of our diabetic patients are shown in Table 1 . Diabetic patients with a higher UAE had signifi cantly higher serum creatinine and lower creatinine clearance levels. Th e serum creatinine level and the 24-h UAE were signifi cantly higher in patients with macroalbuminuria compared with the other groups (Table 1) .
In Table 2 , PAI-1 was statistically signifi cantly diff erent between all groups (P < 0.001), and with the post-hoc Tukey's test for pairwise comparisons, it was signifi cantly higher in diabetic patients in comparison with the control group and signifi cantly higher in diabetic patients with macroalbuminuria in comparison with the other groups. Patients with macroalbuminuria showed signifi cant elevation in the serum level of t-PA when compared with individuals without albuminuria (P < 0.001) and it was higher but of no statistical signifi cance when compared with diabetic patients with microalbuminuria. Th e ratio of PAI-1/t-PA was statistically signifi cantly higher in diabetic patients, with a higher UAE when compared with the control group (P = 0.01).
PAI-1 was strongly correlated with serum creatinine and UAE (P < 0.001) and negatively correlated with creatinine clearance (P = 0.001); t-PA also showed a signifi cantly moderate positive correlation with UAE ( Table 3 and Figs 1-3). 
Table 2 Comparison of PAI-1, t-PA, and PAI/t-PA I between the studied groups
ANOVA Group 1 (mean ± SD) Group 2 (mean ± SD) Group 3 (mean ± SD) Group 4 (mean ± SD) P value PAI-1 (IU/ml) 28 ROC curve analysis revealed that only PAI-1 and t-PA were signifi cant discriminators for macroalbuminu ria and microalbuminuria (P < 0.001) (Tables 4 and 5,  Figs 4 and 5) .
Discussion
Our study showed that the serum level of PAI-1 was statistically signifi cantly higher in diabetic patient subgroups compared with the control group and there was a signifi cant increase in the serum level of PAI-1 in the diabetic patient subgroup in comparison with each other according to the increased UAE, that is, the four groups were statistically signifi cantly diff erent from each other. Also, we found t hat the cutoff point of 73.5 IU/ml was the level of PAI-1 to discriminate macroalbuminuria, and the cutoff point of 43.0 IU/ml was the level of PAI-1 to discriminate microalbuminuria using ROC curve analysis.
Th ese fi ndings were supported by Chudy P et al. [18] , who found that PAI-1 levels were elevated in both diabetic patients with normoalbuminuria and diabetic patients with macroalbuminuria in comparison with the control group. Collins et al. [19] found that an elevated plasma level of PAI-1 mediates diabetic Correlation between plasminogen activator inhibitor-1 (PAI-1) and creatinine in the patient groups.
Figure 1
Correlation between plasminogen activator inhibitor-1 (PAI-1) and the 24-h urinary albumin excretion in the patient groups.
Figure 2
Correlation between tissue-type plasminogen activator (t-PA) and the 24-h urinary albumin excretion in the patient groups. vascular complications and suggested that diabetic nephropathy was the major implication of high PAI-1 levels. Also, Szelag et al. [20] reported that the elevated PAI-1 was associated with diabetic complications, such as microalbuminuria, neuropathy, retinopathy, and lower-extremity arterial diseases, suggesting that circulating PAI-1 may correlate with increased vascular injury.
Bastard et al. [21] had shown that the plasma level of PAI-1 increased in diabetics. Also, Yener et al. [22] observed that the PAI-1 level was signifi cantly elevated in 61 normotensive, normoalbuminuric type 2 diabetic patients without diabetes-related complications. Festa et al. [23] showed that the progression of PAI-1 over time, in addition to high baseline PAI-1 levels, was associated with incident diabetes.
However, Nagi et al. [24] found that the PAI-1 activity was similar between nondiabetic and diabetic patients.
Our study showed a signifi cant increase in the serum level of t-PA in diabetic patients with albuminuria (either microalbuminuria or macroalbuminuria) and that t-PA was a signifi cant discriminator for macroalbuminuria and microalbuminuria and the minimum values of t-PA to discriminate microalbuminuria and macroalbuminuria were 10.25 and 12.5 IU/ml, respectively.
Th is was supported by Beer et al. [25] , who documented increased t-PA and PAI-1 in diabetic patients with and without vascular complications. Also, the prospective study conducted by Wannamethee et al. [26] documented higher levels of t-PA as a risk factor for the development of diabetes in the healthy individuals.
However, Chudy P et al. [18] found that plasma levels of t-PA were not signifi cantly increased in either normoalbuminuric or microalbuminuric diabetic groups compared with controls. AUC, area under the curve; CI, confi dence interval; PAI-1, plasminogen activator inhibitor-l; t-PA, tissue-type plasminogen activator. AUC, area under the curve; CI, confi dence interval; PAI-1, plasminogen activator inhibitor-l; t-PA, tissue-type plasminogen activator.
Receiver operating characteristic (ROC) curves for plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA), and PAI-1/t-PA for discriminating microalbu minuria.
Figure 5
Receiver operating characteristic (ROC) curves for plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA), and PAI-1/t-PA for discriminating macroalbu minuria.
Figure 4
Umpaichitra et al. [27] studied hemostatic factors in 12 type 2 diabetic patients and 17 nondiabetic obese adolescents; they found that PAI-1 activities were signifi cantly greater in diabetic patients than in control individuals, whereas t-PA activities were signifi cantly lower. Th ey concluded that the elevated PAI-1 and lower t-PA activities suppress fi brinolysis in adolescents with type 2 diabetes, adding a risk factor for cardiovascular disease.
Th ese contradictory results concerning t-PA were explained by Sobel et al. [28] , who found that both PAI-1 and total t-PA antigen (free t-PA plus t-PA complex ed with PAI-1) concentrations were increased in association with diabetes, but the concentration of free t-PA and hence the t-PA activity were not increased. Hence, the increased total t-PA is masking the impaired fi brinolytic system activity associated with type 2 diabetes.
We found that the ratio of PAI-1/t-PA in diabetic patients with macroalbuminuria was statistically signifi cantly higher when compared with the control group, that is, diabetic patients with macroalbuminuria had signifi cant elevation in PAI-1/t-PA than the control individuals. Th us, impaired fi brinolysis was higher in diabetic patients with a higher UAE.
Impaired fi brinolysis was related to the activated renin-angiotensin-aldosterone system in type 2 diabetic patients as angiotensin two directly induces the expression of PAI-1 and indirectly through the secre tion of transforming growth factor-b, a potent profi brotic molecule that also induces the expression of PAI-1 and stimulates ECM synthesis and fi brosis [12] . Previous studies found that high doses of angiotensin 2 receptor inhibitor decrease glomerulosclerosis through the inhibition of PAI-1 [10] . Th e combination between decreased ECM degradation due to impaired fi brinolysis and proteolysis with the increased ECM synthesis and fi brosis induced by transforming growth factor-b predispose one to tissue fi brosis, and so increase renal nephropathy and renal mortality [12] .
Our study showed a signifi cantly higher serum creatinine concentration in patients with a higher UAE and impaired fi brinolysis. Th is was supported by the study conducted by Kamgar et al. [12] , who examined the changes that occur in the serum creatinine concentration as an index of kidney function over a 7-year follow-up period in relationship to the fi brinolytic ratio. A marked increase in serum creatinine was observed in patients with a greater UAE and higher PAI-1/t-PA, and they related the association between high PAI-1 and UAE to the endothelial dysfunction that occurs in these diabetic patients.
We found a signifi cant positive correlation between PAI-1 with serum creatinine and the 24-h urinary albumin and a signifi cant negative correlation with creatinine clearance. Regarding t-PA, it showed a signifi cant positive correlation with the 24-h urinary albumin. Hence, the deterioration in renal function was associated with elevations in PAI-1 and t-PA.
We did not fi nd any correlations between PAI-1 and fasting serum lipids. Th is was supported by Ho and Jap [29] In contrast, Lira et al. [30] found a positive correlation between PAI-1 and serum lipids, suggesting that an increased risk of cardiovascular disease associated with a sedentary lifestyle is linked to an elevated PAI-1, and Peter et al. [18] found a positive correlation between PAI-1 levels and triglycerides, which proved that dyslipidemia and hypofi brinolysis are closely linked.
Also, we did not fi nd any correlation between PAI-1 and fasting blood sugar; this was also supported by Ho and Jap [29] who did not fi nd any correlation between PAI-1 activity and the increase in glucose and fasting insulin, but Heldgaard et al. [31] found increased levels of PAI-1 and t-PA to be associated with increased fasting blood sugar.
From this study, we concluded that serum levels of PAI-1 and t-PA and the PAI/t-PA ratio were signifi cantly elevated in type 2 diabetic patients with higher UAE. PAI-1 and t-PA were signifi cantly positively correlated with deteriorations in renal functions. Hence, our study suggested that impaired fi brinolytic activity in type 2 diabetic patients and increased UAE are correlated with the progression of renal disease through deteriorations in renal functions. Th ese results may indicate that in addition to hyperglycemia, hypertension, and dyslipidemia that occur in association with type 2 diabetes, impaired fi brinolysis may be one of the important contributors that predispose one to renal complications.
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